Table 1.
Characteristics of Transplant Centers
| Percentage | p-value | |
|---|---|---|
| Kidney Transplant Program Characteristics From Survey (n=156 centers) | ||
| Organs transplanted: | p<0.001 | |
| Kidney | 100.00 | |
| Pancreas | 66.0 | |
| Liver | 44.9 | |
| Heart | 35.3 | |
| Lung | 23.1 | |
| Other | 5.1 | |
| On-site/on-campus HLA or tissue typing laboratory: | p<0.001 | |
| Yes | 30.1 | |
| No | 69.9 | |
| I don’t know | 0.0 | |
| Tissue typing laboratory accredited by ASHI: | p<0.001 | |
| Yes | 94.9 | |
| No | 0.6 | |
| I don’t know | 3.8 | |
| Percentage of recipients enrolled in a clinical trial: | p<0.001 | |
| None | 23.1 | |
| 1–10% | 27.6 | |
| 11–25% | 26.3 | |
| 26–50% | 14.7 | |
| >50% | 8.3 | |
| Number of FTE clinical research coordinators: | p<0.001 | |
| None | 35.9 | |
| 0.5 FTE | 10.3 | |
| 1.0 FTE | 16.0 | |
| 1.5 FTE | 10.9 | |
| ≥2.0 FTE | 26.3 | |
| ABO-incompatible or crossmatch positive transplants: | p<0.001 | |
| ABO-incompatible | 3.2 | |
| Crossmatch positive | 21.8 | |
| Both | 20.5 | |
| Neither | 54.5 | |
| Participate in PKE and LPE: | p<0.001 | |
| PKE | 29.5 | |
| LPE | 1.9 | |
| Both PKE and LPE | 25.6 | |
| Neither | 41.0 | |
| Laparoscopic living donor nephrectomy: | p<0.001 | |
| Yes | 93.6 | |
| No | 5.8 | |
| Proportion of laparoscopic nephrectomies: | p<0.001 | |
| None | 4.5 | |
| 1–10% | 5.1 | |
| 11–25% | 3.2 | |
| 26–50% | 5.1 | |
| Greater than 50% | 77.6 | |
| Use of electronic medical records: | p<0.001 | |
| Laboratory data | 79.5 | |
| Diagnostic imaging data | 71.8 | |
| Medical history data | 67.9 | |
| Physician order entry | 42.9 | |
| Consultation notes | 59.0 | |
| Evaluate own program’s outcomes regularly: | p<0.001 | |
| Yes | 91.0 | |
| No | 8.3 | |
| Affiliated with a medical school | p<0.001 | |
| Yes | 77.6 | |
| No | 22.4 | |
| Induction therapy used | p<0.001 | |
| Used in essentially all patients | 80.1 | |
| Used on in “high risk” patients | 17.9 | |
| Used hardly ever | 1.3 | |
| First line maintenance for low risk KTRs | p<0.001 | |
| Cyclosporine | 17.3 | |
| Tacrolimus | 91.7 | |
| Mycophenolate mofetil | 95.5 | |
| Azathioprine | 1.3 | |
| Sirolimus | 8.3 | |
| Corticosteroids | 62.8 | |
| Others | 3.8 | |
| First line maintenance for high risk transplant recipients | p<0.001 | |
| Cyclosporine | 7.7 | |
| Tacrolimus | 96.8 | |
| Mycophenolate mofetil | 95.5 | |
| Azathioprine | 0.0 | |
| Sirolimus | 12.8 | |
| Corticosteroids | 81.4 | |
| Others | 1.9 | |
| Formal protocol for post-transplant procedures | ||
| Cardiovascular disease | 53.8 | (p=0.337) |
| CMV infection and disease | 84.6 | (p<0.001) |
| EBV infection and disease | 45.5 | (p=0.296) |
| Influenza | 46.8 | (p=0.519) |
| Polyoma virus nephropathy | 62.2 | (p=0.002) |
| Skin cancer | 46.2 | (p=0.337) |
| Other malignancies | 41.0 | (p=0.025) |
| Steroid-induced osteoporosis | 57.7 | (p=0.055) |
Abbreviations: HLA=human leukocyte antigens; FTE=Full-time equivalent, PKE= paired kidney exchange; LPE= List paired exchange; ASHI= American Society of Histocompatibility and Immunogenetics; KTR= kidney transplant recipients